The Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen is a large psychiatric clinic (125 beds with 2 special wards focused on the treatment of schizophrenic patients and a special day care clinic for schizophrenic patients). The head of Department, Prof. Dr. Dr. Frank Schneider is past president of the German Society for Psychiatry (DGPPN) and is also Director of JARA BRAIN. Under his leadership the Department of Psychiatry, Psychotherapy and Psysomatics ranks first in 2012 among all clinics and institute of the Medical Faculty of the RWTH Aachen University for the fourth time in a row. The Department scored in 2012 340 Impact Points in international scientific journals and acquired third party funding of 2.6 million Euros. In 2012 a centre dedicated to “Mental health for students of the RWTH Aachen” has been opened offering fast and informal advice in crisis due to a variety of early unspecific psychiatric symptoms such as concentration deficits, sleep deficits, high anxiety levels as seen e.g. in the prodromal phase of schizophrenia. The Department is part of a multi-centre study (“Kompetenznetzwerk Schizophrenie”funded by the German Ministry for Education and Research (BMBF) in Germany evaluating prodromal patients and has a long-standing research focus on imaging in schizophrenia.
The Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen is part of a multi-centre study in Germany evaluating prodromal patients and has a long standing research focus on imaging in schizophrenia. Also in interdisciplinary work with Juelich Aachen hosts a DFG funded International Research Training Group “Brain-behavior relationship of emotion and social cognition in schizophrenia and autism” (IRTG1328).
The main task is the transfer of the assembled PET/MR/EEG prototype from phantom measurements into clinical application. For this task imaging protocols will be tailored to individual clinical cases based on the data mining results of WP2. Multimodal imaging results will deliver an individual “fingerprint” of the psychiatric symptoms in a patient and these “fingerprint data” will be put in relation to progress of the disease and response to different treatment regimens. As a close partner to the FZJ, JRB will bring in the clinical perspective into this ambitious engineering project and promote the translation from technical to clinical use.